unopposed estrogen
Recently Published Documents


TOTAL DOCUMENTS

51
(FIVE YEARS 4)

H-INDEX

12
(FIVE YEARS 0)

2021 ◽  
Vol 3 (1) ◽  
pp. 28-33
Author(s):  
Shaikh Zinnat Ara Nasreen ◽  
Nusrat Mahjabeen ◽  
Safinaz Shahreen

The clinical approach to postmenopausal bleeding requires prompt and efficient evaluation to exclude or diagnose endometrial carcinoma and endometrial intraepithelial neoplasia and to find out the real source. Postmenopausal bleeding is ‘endometrial cancer until proven otherwise’, although only 1-14% of such patients will actually have cancer. Clinical risk factors of endometrial carcinoma such as obesity, unopposed estrogen use, polycystic ovary syndrome, diabetes mellitus and family history of gynaecologic malignancy also should be considered during evaluation. Postmenopausal bleeding usually attributed to an intrauterine source, but it may arise from the cervix, vagina, vulva or fallopian tubes & ovaries. The origin of bleeding can also involve non-gynaecologic sites, such as the urethra, bladder, anus/rectum/bowel, or perineum. Meticulous history and thorough physical examination are must. Initial evaluation is by TVS, if endometrial thickness (ET) is <4mm no further evaluation is required but follow up consultation must. If ET is> 4mm, hysteroscopic evaluation and endometrial sampling is recommended Blind endometrial sampling is not accurate as only reveals when endometrial cancer exceeds more than 50% of the endometrial surface area so may be done if hysteroscopic evaluation is not possible. Higher dose of progesterone may be required for endometrial protection when higher doses of estradiol as hormone replacement therapy are used, or in women with high BMI. Unopposed estrogen therapy is associated with a duration and dose-related increase in risk of endometrial hyperplasia and cancer. Endometrial protection requires an adequate dose and duration of progestogen. Endometrial hyperplasia with atypia has much malignant potential but endometrial hyperplasia without atypia may be managed medically with 3 monthly endometrial sampling, if no regression or further progression hysterectomy is the choice of treatment. Finally, patient counseling with discussion of risks /benefits of different options of treatment modalities is the cornerstone of success of addressing postmenopausal bleeding.


2019 ◽  
Vol 60 (4) ◽  
pp. 389-389
Author(s):  
Andrea LaCroix ◽  
Velimir Simunic ◽  
Slobodan Vukicevic

2015 ◽  
Vol 74 (5) ◽  
pp. 445-456 ◽  
Author(s):  
Stanislava Stanojević ◽  
Vesna Kovačević-Jovanović ◽  
Mirjana Dimitrijević ◽  
Vesna Vujić ◽  
Ivana Ćuruvija ◽  
...  

2014 ◽  
Vol 145 (2) ◽  
pp. 449-449
Author(s):  
Gaia Pocobelli ◽  
Polly A. Newcomb ◽  
Christopher I. Li ◽  
Linda S. Cook ◽  
William E. Barlow ◽  
...  

2014 ◽  
Vol 145 (2) ◽  
pp. 439-447 ◽  
Author(s):  
Gaia Pocobelli ◽  
Polly A. Newcomb ◽  
Christopher I. Li ◽  
Linda S. Cook ◽  
William E. Barlow ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document